These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 17516584)

  • 1. Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer.
    Zlobec I; Lugli A; Baker K; Roth S; Minoo P; Hayashi S; Terracciano L; Jass JR
    J Pathol; 2007 Jul; 212(3):260-8. PubMed ID: 17516584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer.
    Minoo P; Baker K; Baumhoer D; Terracciano L; Lugli A; Zlobec I
    Hum Pathol; 2010 Jan; 41(1):70-8. PubMed ID: 19740518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer.
    Zlobec I; Minoo P; Baker K; Haegert D; Khetani K; Tornillo L; Terracciano L; Jass JR; Lugli A
    Eur J Cancer; 2007 Apr; 43(6):1101-7. PubMed ID: 17350821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: a potential role for dysregulation of the transforming growth factor-beta pathway.
    Baker K; Zlobec I; Tornillo L; Terracciano L; Jass JR; Lugli A
    Eur J Cancer; 2007 Feb; 43(3):624-31. PubMed ID: 17223543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients.
    Lugli A; Vlajnic T; Giger O; Karamitopoulou E; Patsouris ES; Peros G; Terracciano LM; Zlobec I
    Hum Pathol; 2011 Dec; 42(12):1833-40. PubMed ID: 21664647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer.
    Zlobec I; Terracciano L; Tornillo L; Günthert U; Vuong T; Jass JR; Lugli A
    Gut; 2008 Oct; 57(10):1413-9. PubMed ID: 18436576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype.
    Paik SS; Jang KS; Song YS; Jang SH; Min KW; Han HX; Na W; Lee KH; Choi D; Jang SJ
    Ann Surg Oncol; 2007 Dec; 14(12):3453-9. PubMed ID: 17882496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and Raf-1 kinase inhibitor protein expression.
    Zlobec I; Baker K; Minoo P; Jass JR; Terracciano L; Lugli A
    Clin Cancer Res; 2008 Jan; 14(1):143-8. PubMed ID: 18172264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local recurrence in mismatch repair-proficient colon cancer predicted by an infiltrative tumor border and lack of CD8+ tumor-infiltrating lymphocytes.
    Zlobec I; Terracciano LM; Lugli A
    Clin Cancer Res; 2008 Jun; 14(12):3792-7. PubMed ID: 18559598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status.
    Kevans D; Wang LM; Sheahan K; Hyland J; O'Donoghue D; Mulcahy H; O'Sullivan J
    Int J Surg Pathol; 2011 Dec; 19(6):751-60. PubMed ID: 21791486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer.
    Karamitopoulou E; Zlobec I; Panayiotides I; Patsouris ES; Peros G; Rallis G; Lapas C; Karakitsos P; Terracciano LM; Lugli A
    Hum Pathol; 2011 Dec; 42(12):1888-96. PubMed ID: 21664646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour budding at invasive margins and outcome in colorectal cancer.
    Kanazawa H; Mitomi H; Nishiyama Y; Kishimoto I; Fukui N; Nakamura T; Watanabe M
    Colorectal Dis; 2008 Jan; 10(1):41-7. PubMed ID: 18078460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic assessment of protein phenotypes characterizing high-grade tumour budding in mismatch repair-proficient colorectal cancer.
    Karamitopoulou E; Lugli A; Panayiotides I; Karakitsos P; Peros G; Rallis G; Patsouris ES; Terracciano L; Zlobec I
    Histopathology; 2010 Aug; 57(2):233-43. PubMed ID: 20716165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel classification of tumour budding in colorectal cancer based on the presence of cytoplasmic pseudo-fragments around budding foci.
    Shinto E; Mochizuki H; Ueno H; Matsubara O; Jass JR
    Histopathology; 2005 Jul; 47(1):25-31. PubMed ID: 15982320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer.
    Zlobec I; Minoo P; Baumhoer D; Baker K; Terracciano L; Jass JR; Lugli A
    Cancer; 2008 Feb; 112(3):495-502. PubMed ID: 18076013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer.
    Zlobec I; Günthert U; Tornillo L; Iezzi G; Baumhoer D; Terracciano L; Lugli A
    Histopathology; 2009 Nov; 55(5):564-75. PubMed ID: 19912362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of tumour-infiltrating lymphocytes and apoptosis in colitis-associated neoplasia: comparison with sporadic colorectal cancer.
    Michael-Robinson JM; Pandeya N; Walsh MD; Biemer-Huttmann AE; Eri RD; Buttenshaw RL; Lincoln D; Clouston AD; Jass JR; Radford-Smith GL
    J Pathol; 2006 Feb; 208(3):381-7. PubMed ID: 16315333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic significance of E-cadherin and liver intestine-cadherin expression in colorectal cancer.
    Kwak JM; Min BW; Lee JH; Choi JS; Lee SI; Park SS; Kim J; Um JW; Kim SH; Moon HY
    Dis Colon Rectum; 2007 Nov; 50(11):1873-80. PubMed ID: 17828401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD24 shows early upregulation and nuclear expression but is not a prognostic marker in colorectal cancer.
    Ahmed MA; Al-Attar A; Kim J; Watson NF; Scholefield JH; Durrant LG; Ilyas M
    J Clin Pathol; 2009 Dec; 62(12):1117-22. PubMed ID: 19946098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer.
    Ngan CY; Yamamoto H; Seshimo I; Ezumi K; Terayama M; Hemmi H; Takemasa I; Ikeda M; Sekimoto M; Monden M
    J Surg Oncol; 2007 Jun; 95(8):652-62. PubMed ID: 17443723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.